



10/509077  
T/EP03/03195



INVESTOR IN PEOPLE

**PRIORITY  
DOCUMENT**  
SUBMITTED OR TRANSMITTED IN  
COMPLIANCE WITH RULE 17.1(a) OR (b)

REC'D 03 JUL 2003

WIPO PCT

The Patent Office  
Concept House  
Cardiff Road  
Newport  
South Wales  
NP10 8QQ

I, the undersigned, being an officer duly authorised in accordance with Section 74(1) and (4) of the Deregulation & Contracting Out Act 1994, to sign and issue certificates on behalf of the Comptroller-General, hereby certify that annexed hereto is a true copy of the documents as originally filed in connection with the patent application identified therein.

In accordance with the Patents (Companies Re-registration) Rules 1982, if a company named in this certificate and any accompanying documents has re-registered under the Companies Act 1980 with the same name as that with which it was registered immediately before re-registration save for the substitution as, or inclusion as, the last part of the name of the company "public limited company" or their equivalents in Welsh, references to the name of the company in this certificate and any accompanying documents shall be treated as references to the name with which it is so re-registered.

In accordance with the rules, the words "public limited company" may be replaced by p.l.c., plc, P.L.C. or PLC.

Re-registration under the Companies Act does not constitute a new legal entity but merely subjects the company to certain additional company law rules.

Signed

Dated 23 April 2003

Patents Act 1977  
(Rule 16)



The Patent Office  
Cardiff Road  
Newport  
Gwent NP9 1RH

# Request for grant of a patent

(See the notes on the back of this form. You can also get an explanatory leaflet from the Patent Office to help you fill in this form)

MG/HG/P33022

1. Your reference

2. Patent application number  
(The Patent Office will fill in his part)

0207275.9

28MAR02 E707145-1 C69803  
P01/7700 0.00-0207275.9

3. Full name, address and postcode of the or of each applicant (underline all surnames)

Glaxo Group Limited  
Glaxo Wellcome House, Berkeley Avenue,  
Greenford, Middlesex UB6 0NN, Great Britain

Patents ADP number (if you know it)

473 587 003

If the applicant is a corporate body, give the country/state of its incorporation

United Kingdom

4. Title of the invention

Novel Compounds

5. Name of your agent (if you have one)

Corporate Intellectual Property

"Address for service" in the United Kingdom to which all correspondence should be sent  
(including the postcode)

GlaxoSmithKline  
Corporate Intellectual Property CN925.1  
980 Great West Road  
BRENTFORD  
Middlesex TW8 9GS

Patents ADP number (if you know it)

8072555006

6. If you are declaring priority from one or more earlier patent applications, give the country and the date of filing of the or each of these earlier applications and (if you know it) the or each application number

Country	Priority application number (if you know it)	Date of filing (day / month / year)
---------	---	--

7. If this application is divided or otherwise derived from an earlier UK application, give the number and the filing date of the earlier application

Number of earlier application	Date of filing (day / month / year)
-------------------------------	--

8. Is a statement of inventorship and of right to grant of a patent required in support of this request? (Answer yes if:

- a) any applicant named in part 3 is not an inventor, or
  - b) there is an inventor who is named as an applicant, or
  - c) any named applicant is a corporate body
- See note (d)

**Patents Form 1/77**

Enter the number of sheets for any of the following items you are filing with this form.  
Do not count copies of the same document

Continuation sheets of this form	
Description	10
Claim(s)	2
Abstract	
Drawings	



10. If you are also filing any of the following, state how many against each item.

**Priority Documents**

Translations of priority documents

Statement of inventorship and right to grant of a patent (*Patents Form 7/77*)

Request for preliminary examination and search (*Patents Form 9/77*)

Request for substantive examination (*Patents Form 10/77*)

Any other documents  
(please specify)

We request the grant of a patent on the basis of this application

Signature  Date 27-Mar-02

S C Hockley

12. Name and daytime telephone number of person to contact in the United Kingdom

S C Hockley 01279 644355

**Warning**

*After an application for a Patent has been filed, the Comptroller of the Patent Office will consider whether publication or communication of the invention should be prohibited or restricted under Section 22 of the Patents Act 1977. You will be informed if it is necessary to prohibit or restrict your invention in this way. Furthermore, if you live in the United Kingdom, Section 23 of the Patents Act 1977 stops you from applying for a patent abroad without first getting written permission unless an application has been filed at least six weeks beforehand in the United Kingdom for a patent for the same invention and either no direction prohibiting publication or communication has been given, or any such direction has been revoked.*

**Notes**


- a) If you need help to fill in this form or you have any questions, please contact the Patent Office on 0645 500505
- b) Write your answers in capital letters using black ink or you may type them.
- c) If there is not enough space for all relevant details on any part of this form, please continue on a separate sheet of paper and write "see continuation sheet" in the relevant part(s). Any continuation sheet should be attached to this form.
- d) If you have answered 'Yes' *Patents Form 7/77* will need to be filed.
- f) For details of the fee and ways to pay please contact the Patent Office.

## NOVEL COMPOUNDS

This invention relates to novel quinoline compounds having pharmacological activity, processes for their preparation, to compositions containing them and to their use in the treatment of CNS and other disorders.

- WO 98/27081 discloses a series of aryl sulphonamide compounds that are said to be 5-HT<sub>6</sub> receptor antagonists and which are claimed to be useful in the treatment of various CNS disorders. GB-2341549, WO 99/47516 and WO 99/65906 all disclose a series of indole derivatives that are claimed to 5-HT<sub>6</sub> receptor affinity. JP 02262627 (Japan Synthetic Rubber Co) describes a series of substituted quinoline derivatives useful as wavelength converting elements. WO 01/83456 (Yamanouchi Pharmaceutical Co. Ltd) describe a series of bicyclic or tricyclic fused heteroaryl compounds with phosphatidylinositol 3-kinase activity. WO 00/42026 (Novo Nordisk) describes a series of quinoline and quinoxaline compounds for use as GLP-1 agonists. JP 08003144 (Chugai Pharmaceutical Co. Ltd.) describe a series of quinazoline and quinoline derivatives as potassium channel openers.

- A structurally novel class of compounds has now been found which also possess affinity for the 5-HT<sub>6</sub> receptor. The present invention therefore provides, in a first aspect, a compound of formula (I) or a pharmaceutically acceptable salt thereof:



(I)

wherein:

- 25 R¹ and R² independently represent hydrogen or C<sub>1-6</sub> alkyl or R¹ is linked to R² to form a group (CH<sub>2</sub>)<sub>2</sub>, (CH<sub>2</sub>)<sub>3</sub> or (CH<sub>2</sub>)<sub>4</sub>;  
 R³ and R⁴ independently represent hydrogen, halogen, cyano, -CF<sub>3</sub>, -CF<sub>3</sub>O, C<sub>1-6</sub> alkyl, C<sub>1-6</sub> alkoxy, C<sub>1-6</sub> alkanoyl or a group -CONR⁵R⁶;  
 R⁵ and R⁶ independently represent hydrogen or C<sub>1-6</sub> alkyl or together may be fused to form a 5- to  
 30 7- membered aromatic or non-aromatic heterocyclic ring optionally interrupted by an O or S atom;  
 m represents an integer from 1 to 4, when m is an integer greater than 1, two R² groups may instead be linked to form a group CH<sub>2</sub>, (CH<sub>2</sub>)<sub>2</sub> or (CH<sub>2</sub>)<sub>3</sub>;  
 n and p independently represent 1 or 2;

q represents an integer from 1 to 3;

A represents a group  $-\text{Ar}^1$  or  $-\text{Ar}^2\text{Ar}^3$ ;

$\text{Ar}^1$ ,  $\text{Ar}^2$  and  $\text{Ar}^3$  independently represent an aryl group or a heteroaryl group, both of which may be optionally substituted by one or more (eg. 1, 2 or 3) substituents which may be the same or

- 5 different, and which are selected from the group consisting of halogen, hydroxy, cyano, nitro, trifluoromethyl, trifluoromethoxy,  $\text{C}_{1-6}$  alkyl, trifluoromethanesulfonyloxy, pentafluoroethyl,  $\text{C}_{1-6}$  alkoxy, aryl $\text{C}_{1-6}$  alkoxy,  $\text{C}_{1-6}$  alkylthio,  $\text{C}_{1-6}$  alkoxy $\text{C}_{1-6}$  alkyl,  $\text{C}_{3-7}$  cycloalkyl $\text{C}_{1-6}$  alkoxy,  $\text{C}_{1-6}$  alkanoyl,  $\text{C}_{1-6}$  alkoxycarbonyl,  $\text{C}_{1-6}$  alkylsulfonyl,  $\text{C}_{1-6}$  alkylsulfinyl,  $\text{C}_{1-6}$  alkylsulfonyloxy,  $\text{C}_{1-6}$  alkylsulfonyl $\text{C}_{1-6}$  alkyl, arylsulfonyl, arylsulfonyloxy, arylsulfonyl $\text{C}_{1-6}$  alkyl,  $\text{C}_{1-6}$  alkylsulfonamido,  $\text{C}_{1-6}$  alkylamido,  $\text{C}_{1-6}$  alkylsulfonamido $\text{C}_{1-6}$  alkyl,  $\text{C}_{1-6}$  alkylamido $\text{C}_{1-6}$  alkyl, arylsulfonamido, arylcarboxamido, arylsulfonamido $\text{C}_{1-6}$  alkyl, arylcarboxamido $\text{C}_{1-6}$  alkyl, aroyl, aroyl $\text{C}_{1-6}$  alkyl, aryl $\text{C}_{1-6}$  alkanoyl, or a group  $\text{CONR}^7\text{R}^8$  or  $\text{SO}_2\text{NR}^7\text{R}^8$ , wherein  $\text{R}^7$  and  $\text{R}^8$  independently represent hydrogen or  $\text{C}_{1-6}$  alkyl or together may be fused to form a 5- to 7-membered aromatic or non-aromatic heterocyclic ring optionally interrupted by an O or S atom; 10 or solvates thereof.

- Alkyl groups, whether alone or as part of another group, may be straight chain or branched and the groups alkoxy and alkanoyl shall be interpreted similarly: Alkyl moieties are more preferably  $\text{C}_{1-4}$  alkyl, eg. methyl or ethyl. The term 'halogen' is used herein to describe, unless otherwise 20 stated, a group selected from fluorine, chlorine, bromine or iodine.

The term "aryl" includes phenyl and naphthyl.

- The term "heteroaryl" is intended to mean a 5-7 membered aromatic ring or a fused 8-10 25 membered bicyclic aromatic ring containing 1 to 3 heteroatoms selected from oxygen, nitrogen and sulphur. Suitable examples of such monocyclic aromatic rings include thienyl, furyl, pyrrolyl, triazolyl, imidazolyl, oxazolyl, thiazolyl, oxadiazolyl, isothiazolyl, isoxazolyl, thiadiazolyl, pyrazolyl, pyrimidyl, pyridazinyl, pyrazinyl and pyridyl. Suitable examples of such fused aromatic rings include benzofused aromatic rings such as quinoliny, isoquinoliny, 30 quinazolinyl, quinoxalinyl, cinnoliny, naphthyridinyl, indolyl, indazolyl, pyrrolopyridinyl, benzofuranyl, benzothienyl, benzimidazolyl, benzoxazolyl, benzisoxazolyl, benzothiazolyl, benzisothiazolyl, benzoxadiazolyl, benzothiadiazolyl and the like. Heteroaryl groups, as described above, may be linked to the remainder of the molecule via a carbon atom or, when present, a suitable nitrogen atom except where otherwise indicated above.

- 35 It will be appreciated that wherein the above mentioned aryl or heteroaryl groups have more than one substituent, said substituents may be linked to form a ring, for example a carboxyl and amine group may be linked to form an amide group.

- 40 Preferably,  $\text{R}^1$  represents hydrogen or methyl, more preferably hydrogen.  
Preferably  $\text{R}^2$  represents hydrogen.  
Preferably  $\text{R}^3$  represents hydrogen, methyl or halogen, more preferably hydrogen or methyl.  
Preferably  $\text{R}^4$  represents hydrogen or halogen, more preferably hydrogen.

Preferably m, n, p and q each represent 1.

When A represents a group  $-Ar^1$ ,  $Ar^1$  preferably represents optionally substituted phenyl or pyridyl, more preferably phenyl optionally substituted with halogen, cyano, trifluoromethyl or trifluoromethoxy. Particularly preferred  $Ar^1$  is unsubstituted phenyl.

- 5 When A represents a group  $-Ar^2-Ar^3$ ,  $Ar^2$  and  $Ar^3$  preferably both independently represent phenyl or monocyclic heteroaryl group as defined above;  
Preferably A represents a group  $-Ar^1$ .

- 10 Preferred compounds according to the invention include example E1 as shown below, or a pharmaceutically acceptable salt thereof.


The compounds of formula (I) can form acid addition salts thereof. It will be appreciated that for use in medicine the salts of the compounds of formula (I) should be pharmaceutically acceptable. Suitable pharmaceutically acceptable salts will be apparent to those skilled in the art and include those described in J. Pharm. Sci., 1977, 66, 1-19, such as acid addition salts formed with inorganic acids e.g. hydrochloric, hydrobromic, sulfuric, nitric or phosphoric acid; and organic acids e.g. succinic, maleic, acetic, fumaric, citric, tartaric, benzoic, p-toluenesulfonic, methanesulfonic or naphthalenesulfonic acid. The present invention includes within its scope all possible stoichiometric and non-stoichiometric forms.

20 The compounds of formula (I) may be prepared in crystalline or non-crystalline form, and, if crystalline, may optionally be solvated, eg. as the hydrate. This invention includes within its scope stoichiometric solvates (eg. hydrates) as well as compounds containing variable amounts of solvent (eg. water).

25 Certain compounds of formula (I) are capable of existing in stereoisomeric forms (e.g. diastereomers and enantiomers) and the invention extends to each of these stereoisomeric forms and to mixtures thereof including racemates. The different stereoisomeric forms may be separated one from the other by the usual methods, or any given isomer may be obtained by stereospecific or asymmetric synthesis. The invention also extends to any tautomeric forms and mixtures thereof.

30 The present invention also provides a process for the preparation of a compound of formula (I) or a pharmaceutically acceptable salt thereof, which process comprises:

- 35 (a) reacting a compound of formula (II)



wherein  $R^{1a}$  is as defined for  $R^1$  or an  $N$ -protecting group,  $R^2$ ,  $R^3$ ,  $R^4$ ,  $m$ ,  $n$ ,  $p$  and  $q$  are as defined above and  $L^1$  is a suitable leaving group such as iodo or trifluoromethylsulfonyloxy;

- 5 with a compound of formula  $A-SO_2H$ , (or  $A-SH$  followed by a subsequent oxidation step) wherein  $A$  is as defined above and thereafter as necessary removing an  $R^{1a}$   $N$ -protecting group;

(b) deprotecting a compound of formula (I) which is protected; and thereafter optionally

- 10 (c) interconversion to other compounds of formula (I) and/or forming a pharmaceutically acceptable salt and/or solvate.

The  $N$ -protecting group used may be any conventional group e.g. *t*-butoxycarbonyl (Boc) or benzyloxycarbonyl.

- 15 Process (a) wherein a compound of formula (II) is reacted with a compound of formula  $A-SO_2H$  typically comprises use of basic conditions and may be most conveniently carried out by using a suitable salt of the compound  $A-SO_2H$  (e.g. the sodium salt) in an appropriate solvent such as  $N,N$ -dimethylformamide, in the presence of a transition metal salt such as copper (I) iodide.


- 20 Process (a) wherein a compound of formula (II) is reacted with a compound of formula  $A-SH$  typically comprises use of basic conditions e.g. by using a suitable salt of the compound  $A-SH$  (e.g. the sodium salt) in an appropriate solvent such as  $N,N$ -dimethylformamide, in the presence of a suitable metal salt such as copper (I) iodide, followed by use of a suitable oxidant such as 3-chloroperbenzoic acid, peracetic acid or potassium monopersulfate.

- In processes (a) and (b), examples of protecting groups and the means for their removal can be found in T. W. Greene 'Protective Groups in Organic Synthesis' (J. Wiley and Sons, 1991). Suitable amine protecting groups include sulphonyl (e.g. tosyl), acyl (e.g. acetyl, 2',2',2'-trichloroethoxycarbonyl, benzyloxycarbonyl or *t*-butoxycarbonyl) and arylalkyl (e.g. benzyl), which may be removed by hydrolysis (e.g. using an acid such as hydrochloric acid) or reductively (e.g. hydrogenolysis of a benzyl group or reductive removal of a 2',2',2'-trichloroethoxycarbonyl group using zinc in acetic acid) as appropriate. Other suitable amine protecting groups include trifluoroacetyl ( $-COCF_3$ ) which may be removed by base catalysed hydrolysis or a solid phase resin bound benzyl group, such as a Merrifield resin bound 2,6-dimethoxybenzyl group (Ellman
- 30
- 35
- which may be removed by acid catalysed hydrolysis, for example with trifluoroacetic

acid. A further amine protecting group includes methyl which may be removed using standard methods for N-dealkylation (e.g. 1-chloroethyl chloroformate under basic conditions followed by treatment with methanol).

- 5 Process (c) may be performed using conventional interconversion procedures such as epimerisation, oxidation, reduction, alkylation, nucleophilic or electrophilic aromatic substitution, ester hydrolysis or amide bond formation. For example, N-dealkylation of a compound of formula (I) wherein  $R^1$  represents an alkyl group to give a compound of formula (I) wherein  $R^1$  represents hydrogen. It will be appreciated that such interconversion may be.
- 10 interconversion of protected derivatives of formula (I) which may subsequently be deprotected following interconversion.

Compounds of formula (II) may be prepared in accordance with the following process:



15 wherein  $R^{1a}$  is as defined above for  $R^1$  or an N-protecting group,  $R^2$ ,  $R^3$ ,  $R^4$ , m, n, p and q are as defined above,  $L^1$  represents a suitable leaving group, such as iodo or trifluoromethylsulfonyloxy and  $L^2$  represents a suitable leaving group, such as chlorine.

20 Step (i) typically comprises reacting a compound of formula (III) with a suitable oxidant such as a peracid (e.g. 3-chloroperbenzoic acid or peracetic acid) in an inert solvent such as



dichloromethane in order to generate the quinoline-*N*-oxide, followed by a combination of Lewis acid and nucleophile; for example this latter step may be advantageously carried out using phosphorus oxychloride.

- 5 Step (ii) typically comprises heating a mixture of compounds of formula (IV) and (V) in a suitable solvent such as ethanol, optionally in the presence of additional base (e.g. triethylamine or an excess of the compound of formula (V)).

- 10 Compounds of formula (III) and (V) are known in the literature or can be prepared by analogous methods.

Pharmaceutically acceptable salts may be prepared conventionally by reaction with the appropriate acid or acid derivative.

- 15 Compounds of formula (I) and their pharmaceutically acceptable salts have affinity for the 5-HT<sub>6</sub> receptor and are believed to be of potential use in the treatment of certain CNS disorders such as anxiety, depression, epilepsy, obsessive compulsive disorders, migraine, cognitive memory disorders (e.g. Alzheimers disease, age related cognitive decline and mild cognitive impairment), Parkinsons Disease, ADHD (Attention Deficit Disorder/Hyperactivity Syndrome), sleep  
20 disorders (including disturbances of Circadian rhythm), feeding disorders such as anorexia and bulimia, panic attacks, withdrawal from drug abuse such as cocaine, ethanol, nicotine and benzodiazepines, schizophrenia, and also disorders associated with spinal trauma and/or head injury such as hydrocephalus. Compounds of the invention are also expected to be of use in the treatment of certain GI (gastrointestinal) disorders such as IPS (Irritable Bowel Syndrome).  
25 Compounds of the invention are also expected to be of use in the treatment of obesity.

- Thus the invention also provides a compound of formula (I) or a pharmaceutically acceptable salt thereof, for use as a therapeutic substance, in particular in the treatment or prophylaxis of the above disorders. In particular the invention provides for a compound of formula (I) or a  
30 pharmaceutically acceptable salt thereof, for use in the treatment of depression, anxiety, obesity and cognitive memory disorders

- The invention further provides a method of treatment or prophylaxis of the above disorders, in mammals including humans, which comprises administering to the sufferer a therapeutically  
35 effective amount of a compound of formula (I) or a pharmaceutically acceptable salt thereof.

- In another aspect, the invention provides the use of a compound of formula (I) or a pharmaceutically acceptable salt thereof in the manufacture of a medicament for use in the treatment or prophylaxis of the above disorders.  
40

In order to use the compounds of formula (I) in therapy, they will normally be formulated into a pharmaceutical composition in accordance with standard pharmaceutical practice. The present

invention also provides a pharmaceutical composition, which comprises a compound of formula (I) or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier.

5 A pharmaceutical composition of the invention, which may be prepared by admixture, suitably at ambient temperature and atmospheric pressure, is usually adapted for oral, parenteral or rectal administration and, as such, may be in the form of tablets, capsules, oral liquid preparations, powders, granules, lozenges, reconstitutable powders, injectable or infusible solutions or suspensions or suppositories. Orally administrable compositions are generally preferred.

10 Tablets and capsules for oral administration may be in unit dose form, and may contain conventional excipients, such as binding agents, fillers, tableting lubricants, disintegrants and acceptable wetting agents. The tablets may be coated according to methods well known in normal pharmaceutical practice.

15 Oral liquid preparations may be in the form of, for example, aqueous or oily suspension, solutions, emulsions, syrups or elixirs, or may be in the form of a dry product for reconstitution with water or other suitable vehicle before use. Such liquid preparations may contain conventional additives such as suspending agents, emulsifying agents, non-aqueous vehicles (which may include edible oils), preservatives, and, if desired, conventional flavourings or  
20 colourants.

For parenteral administration, fluid unit dosage forms are prepared utilising a compound of the invention or pharmaceutically acceptable salt thereof and a sterile vehicle. The compound, depending on the vehicle and concentration used, can be either suspended or dissolved in the  
25 vehicle. In preparing solutions, the compound can be dissolved for injection and filter sterilised before filling into a suitable vial or ampoule and sealing. Advantageously, adjuvants such as a local anaesthetic, preservatives and buffering agents are dissolved in the vehicle. To enhance the stability, the composition can be frozen after filling into the vial and the water removed under vacuum. Parenteral suspensions are prepared in substantially the same manner, except that the  
30 compound is suspended in the vehicle instead of being dissolved, and sterilization cannot be accomplished by filtration. The compound can be sterilised by exposure to ethylene oxide before suspension in a sterile vehicle. Advantageously, a surfactant or wetting agent is included in the composition to facilitate uniform distribution of the compound.

35 The composition may contain from 0.1% to 99% by weight, preferably from 10 to 60% by weight, of the active material, depending on the method of administration.

The dose of the compound used in the treatment of the aforementioned disorders will vary in the usual way with the seriousness of the disorders, the weight of the sufferer, and other similar  
40 factors. However, as a general guide suitable unit doses may be 0.05 to 1000 mg, more suitably 0.05 to 200 mg, for example 20 to 40 mg; and such unit doses will preferably be administered once a day, although administration more than once a day may be required; and such therapy may extend for a number of weeks or months.

All publications, including but not limited to patents and patent applications, cited in this specification are herein incorporated by reference as if each individual publication were specifically and individually indicated to be incorporated by reference herein as though fully set forth.

5

The following Descriptions and Examples illustrate the preparation of compounds of the invention.

#### Description 1

##### 10 7-Iodo-2-methylquinoline (D1)

Crotonaldehyde (4.96 ml, 60.0 mmol) was added dropwise over 1 h, *via* syringe pump, to a solution of 3-iodoaniline (12.5 g, 57.0 mmol) in 5M HCl (30 ml) at 90 °C. The reaction mixture was then heated at 100 °C for 3 h, before being cooled to room temperature and washed with Et<sub>2</sub>O. To the aqueous solution was then added approx. 1 eq. of zinc (II) chloride, with vigorous stirring. The solution was then cooled to 0 °C and stirred for 45 min. The solid material was filtered off and washed (x 2) with cold 5M HCl. The crude product was dried on a filter paper and then stirred as a suspension in 2-propanol. The zinc chloride salt was filtered, dried and then re-suspended in water. The stirred mixture was basified with conc. ammonium hydroxide and the resultant slurry extracted with EtOAc (3 x 100 ml). The combined organic layers were dried (Na<sub>2</sub>SO<sub>4</sub>) and the solvents evaporated *in vacuo* to give the free base as a dark green oil. This material was then dissolved in MeOH and 1.1 eq. of 1M HCl in Et<sub>2</sub>O added. The solvents were then evaporated *in vacuo* to give a dark green solid. Re-crystallisation from MeOH gave the hydrochloride salt as a green solid. The free base was regenerated by stirring a suspension of the solid in saturated aqueous NaHCO<sub>3</sub> and extraction with dichloromethane to give the title compound (D1) (0.9 g).

25

NMR (CDCl<sub>3</sub>):  $\delta_{\text{H}}$  2.74 (3H, s), 7.30 (1H, d,  $J = 8.4$  Hz), 7.49 (1H, d,  $J = 8.5$  Hz), 7.74 (1H, dd,  $J = 1.6, 8.5$  Hz), 8.00 (1H, d,  $J = 8.4$  Hz), 8.46 (1H, s)

Mass Spectrum: C<sub>10</sub>H<sub>8</sub>IN requires 269; found: 270 (MH<sup>+</sup>).

##### 30 Description 2

##### 4-Chloro-7-iodo-2-methylquinoline (D2)

To a solution of 7-iodo-2-methylquinoline (D1) (1.6 g, 5.95 mmol) in chloroform (30 ml) was added 3-chloroperbenzoic acid (~ 50 %, 2.46 g, 7.14 mmol) in one portion. The reaction mixture was stirred at room temperature for 1 h, diluted with dichloromethane (100 ml) and then washed with saturated aqueous NaHCO<sub>3</sub>. The aqueous layer was re-extracted with dichloromethane and the combined organic layers dried (Na<sub>2</sub>SO<sub>4</sub>) and the solvents evaporated *in vacuo* to give 7-iodo-2-methylquinoline-*N*-oxide as an orange oil which was used without further purification. To a stirred solution of the 7-iodo-2-methylquinoline-*N*-oxide (1.70 g, 5.96 mmol) in dichloromethane (50 ml) was added POCl<sub>3</sub> (0.61 ml, 6.56 mmol) at 0 °C, under argon. Reaction mixture was stirred at room temperature for 12 h before a further 1 eq. of POCl<sub>3</sub> was added. Reaction mixture was then heated at 50 °C for 1.5 h, a further 1 eq. of POCl<sub>3</sub> added and the reaction heated at 60 °C for 2 h. After this period, the reaction mixture was cooled to room temperature and poured into ice / water (300 ml), basified with 0.88 NH<sub>3</sub> and extracted with dichloromethane (3 x 100 ml).

40

Combined organic layers were washed with water (100 ml), dried ( $\text{Na}_2\text{SO}_4$ ) and solvents evaporated *in vacuo* to give a brown oil. Purification by flash chromatography (5% EtOAc in PE) gave the title compound as a yellow solid (D2) (485 mg).

NMR ( $\text{CDCl}_3$ ) :  $\delta_{\text{H}}$  2.71 (3H, s), 7.40 (1H, s), 7.83 (1H, dd,  $J = 1.6, 8.8$  Hz), 7.88 (1H, d,  $J = 8.8$  Hz), 8.46 (1H, d,  $J = 1.6$  Hz) -

5 Mass Spectrum :  $\text{C}_{10}\text{H}_7^{35/37}\text{ClIN}$  requires 303 / 305; Found 304 / 306 ( $\text{MH}^+$ )

### Description 3

#### 4-(4-*tert*-Butyloxycarbonyl)piperazin-1-yl-7-iodo-2-methylquinoline (D3)

10 A mixture of 4-chloro-7-iodo-2-methylquinoline (D2) (475 mg, 1.56 mmol) and 1-Boc-piperazine (348 mg, 1.88 mmol) in ethanol (2 ml) were heated at 130 °C for 4 h in a sealed vessel. The reaction mixture was then cooled, the solvent evaporated *in vacuo* and the residue partitioned between dichloromethane and saturated aqueous  $\text{NaHCO}_3$ . The aqueous layer was re-extracted with dichloromethane (x 2) and the combined organic layers dried ( $\text{Na}_2\text{SO}_4$ ) and the solvent

15 evaporated *in vacuo* to give a yellow oil. Purification by flash chromatography (EtOAc / PE) gave the title compound as a yellow solid (D3) (485 mg).

NMR ( $\text{CDCl}_3$ ) :  $\delta_{\text{H}}$  1.50 (9H, s), 2.66 (3H, s), 3.12-3.14 (4H, m), 3.68-3.71 (4H, m), 6.74 (1H, s), 7.66-7.68 (2H, m), 8.40 (1H, d,  $J = 1.6$  Hz)

Mass Spectrum :  $\text{C}_{19}\text{H}_{24}\text{IN}_3\text{O}_2$  requires 453; Found 454 ( $\text{MH}^+$ )

20

### Description 4

#### 4-(4-*tert*-Butyloxycarbonyl)piperazin-1-yl-2-methyl-7-phenylsulfonylquinoline (D4)

A mixture of 4-(4-*tert*-butyloxycarbonyl)piperazin-1-yl-7-iodo-2-methylquinoline (D3) (100 mg, 0.22 mmol), phenylsulfinic acid sodium salt (132 mg, 0.66 mmol) and CuI (126 mg, 0.66 mmol) were stirred together under argon, excluding light for 20 min. DMF (5 ml) was then added

25 the reaction heated at 120 °C for 24 h. the reaction mixture was then cooled to room temperature and partitioned between water (60 ml) and dichloromethane (60 ml). Aqueous layer was re-extracted with dichloromethane and the combined organic layers washed with water, dried ( $\text{Na}_2\text{SO}_4$ ) and the solvents evaporated *in vacuo* to give a yellow oil. Purification by flash

30 chromatography (EtOAc / PE) gave the title compound as an off-white solid (D4) (65 mg)

NMR ( $\text{CDCl}_3$ ) :  $\delta_{\text{H}}$  1.50 (9H, s), 2.69 (3H, s), 3.11-3.14 (4H, m), 3.68-3.71 (4H, m), 6.81 (1H, s), 7.48-7.56 (3H, m), 7.89 (1H, d,  $J = 8$  Hz), 8.00-8.07 (3H, m), 8.59 (1H, d,  $J = 2$  Hz)

Mass Spectrum :  $\text{C}_{25}\text{H}_{29}\text{N}_3\text{O}_4\text{S}$  requires 467; Found 468 ( $\text{MH}^+$ )

### 35 Example 1

#### 2-Methyl-4-piperazin-1-yl-7-phenylsulfonylquinoline hydrochloride (E1)

To a stirred solution of 4-(4-*tert*-butyloxycarbonyl)piperazin-1-yl-2-methyl-7-phenylsulfonylquinoline (D4) (60 mg, 0.128 mmol) in dichloromethane (10 ml) was added trifluoroacetic acid (2 ml) dropwise. Reaction mixture was stirred for 1 h and solvents evaporated

40 *in vacuo* and partitioned between dichloromethane and saturated aqueous  $\text{K}_2\text{CO}_3$ . Aqueous layer was re-extracted with dichloromethane (x 2) and the combined organic layers dried ( $\text{Na}_2\text{SO}_4$ ) and the solvents evaporated *in vacuo* to give a colourless oil. This material was dissolved in

dichloromethane / MeOH and treated with 1.1 eq. of 1M HCl in Et<sub>2</sub>O. The solvents were evaporated *in vacuo* to give the title compound as a pale yellow solid (E1) (45 mg)

NMR (DMSO-d<sub>6</sub>) :  $\delta_{\text{H}}$  2.67 (3H, s), 3.30-3.60 (8H, br m), 7.22 (1H, s), 7.64-7.75 (4H, m), 7.89-7.91 (1H, d,  $J = 8.6$  Hz), 8.05 (3H, d,  $J = 7.5$  Hz), 8.25 (1H, d,  $J = 8.7$  Hz), 9.45 (2H, br s)

5 Mass Spectrum : C<sub>20</sub>H<sub>21</sub>N<sub>3</sub>O<sub>2</sub>S requires 353; Found 354 (MH<sup>+</sup>)


Pharmacological data

Compounds can be tested following the procedures outlined in WO98/27081.

10 The compound of Example E1 was tested and showed good affinity for the 5-HT<sub>6</sub> receptor, having a pK<sub>i</sub> value > 8.0 at human cloned 5-HT<sub>6</sub> receptors.

## Claims:

1. A compound of formula (I) or a pharmaceutically acceptable salt thereof:



(I)

wherein:

R¹ and R² independently represent hydrogen or C<sub>1-6</sub> alkyl or R¹ is linked to R² to form a group (CH<sub>2</sub>)<sub>2</sub>, (CH<sub>2</sub>)<sub>3</sub> or (CH<sub>2</sub>)<sub>4</sub>;

- 10 R³ and R⁴ independently represent hydrogen, halogen, cyano, -CF<sub>3</sub>, -CF<sub>3</sub>O, C<sub>1-6</sub> alkyl, C<sub>1-6</sub> alkoxy, C<sub>1-6</sub> alkanoyl or a group -CONR⁵R⁶;

R⁵ and R⁶ independently represent hydrogen or C<sub>1-6</sub> alkyl or together may be fused to form a 5- to 7- membered aromatic or non-aromatic heterocyclic ring optionally interrupted by an O or S atom;

- 15 m represents an integer from 1 to 4, if m is an integer greater than 1, two R² groups may instead be linked to form a group CH<sub>2</sub>, (CH<sub>2</sub>)<sub>2</sub> or (CH<sub>2</sub>)<sub>3</sub>;

n and p independently represent 1 or 2;

q represents an integer from 1 to 3;

A represents a group -Ar¹ or -Ar²Ar³;

- 20 Ar¹, Ar² and Ar³ independently represent an aryl group or a heteroaryl group, both of which may be optionally substituted by one or more (eg. 1, 2 or 3) substituents which may be the same or different, and which are selected from the group consisting of halogen, hydroxy, cyano, nitro, trifluoromethyl, trifluoromethoxy, C<sub>1-6</sub> alkyl, trifluoromethanesulfonyloxy, pentafluoroethyl, C<sub>1-6</sub> alkoxy, arylC<sub>1-6</sub> alkoxy, C<sub>1-6</sub> alkylthio, C<sub>1-6</sub> alkoxyC<sub>1-6</sub> alkyl, C<sub>3-7</sub> cycloalkylC<sub>1-6</sub> alkoxy, C<sub>1-6</sub> alkanoyl, C<sub>1-6</sub> alkoxy carbonyl, C<sub>1-6</sub> alkylsulfonyl, C<sub>1-6</sub> alkylsulfinyl, C<sub>1-6</sub> alkylsulfonyloxy, C<sub>1-6</sub> alkylsulfonylC<sub>1-6</sub> alkyl, arylsulfonyl, arylsulfonyloxy, arylsulfonylC<sub>1-6</sub> alkyl, C<sub>1-6</sub> alkylsulfonamido, C<sub>1-6</sub> alkylamido, C<sub>1-6</sub> alkylsulfonamidoC<sub>1-6</sub> alkyl, C<sub>1-6</sub> alkylamidoC<sub>1-6</sub> alkyl, arylsulfonamido, arylcarboxamido, arylsulfonamidoC<sub>1-6</sub> alkyl, arylcarboxamidoC<sub>1-6</sub> alkyl, aroyl, aroylC<sub>1-6</sub> alkyl, arylC<sub>1-6</sub> alkanoyl, or a group CONR⁷R⁸ or SO<sub>2</sub>NR⁷R⁸, wherein R⁷ and R⁸

- 30 independently represent hydrogen or C<sub>1-6</sub> alkyl or together may be fused to form a 5- to 7- membered aromatic or non-aromatic heterocyclic ring optionally interrupted by an O or S atom; or solvates thereof.

2. A compound according to claim 1 which is a compound of formula E1 or a pharmaceutically acceptable salt thereof.

3. A compound according to claim 1 or claim 2 for use in therapy.

4. A compound according to claim 1 or claim 2 for use in the treatment of depression, anxiety, obesity and cognitive memory disorders.

5. A pharmaceutical composition which comprises a compound according to claim 1 or claim 2 and a pharmaceutically acceptable carrier or excipient.

**This Page is Inserted by IFW Indexing and Scanning  
Operations and is not part of the Official Record**

**BEST AVAILABLE IMAGES**

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images include but are not limited to the items checked:

- ☐ BLACK BORDERS
- ☐ IMAGE CUT OFF AT TOP, BOTTOM OR SIDES
- ☒ FADED TEXT OR DRAWING
- ☐ BLURRED OR ILLEGIBLE TEXT OR DRAWING
- ☐ SKEWED/SLANTED IMAGES
- ☐ COLOR OR BLACK AND WHITE PHOTOGRAPHS
- ☐ GRAY SCALE DOCUMENTS
- ☒ LINES OR MARKS ON ORIGINAL DOCUMENT
- ☐ REFERENCE(S) OR EXHIBIT(S) SUBMITTED ARE POOR QUALITY
- ☐ OTHER: \_\_\_\_\_

**IMAGES ARE BEST AVAILABLE COPY.**

**As rescanning these documents will not correct the image problems checked, please do not report these problems to the IFW Image Problem Mailbox.**